key: cord-0802912-guxvzo7u authors: Epstein, Samantha; Xia, Zongqi; Lee, Annie; Dahl, Megan; Edwards, Keith; Levit, Elle; Longbrake, Erin E.; Perrone, Christopher; Kavak, Katelyn; Weinstock-Guttman, Bianca; Diallo, Fatoumata; Ricci, Adelle; Riley, Claire; De Jager, Philip L.; Farber, Rebecca; Wesley, Sarah F. title: Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data date: 2021-12-02 journal: Mult Scler Relat Disord DOI: 10.1016/j.msard.2021.103433 sha: 7824934994a9072b68163fbe6f420a982be2d4ab doc_id: 802912 cord_uid: guxvzo7u Background: Patients with autoimmune disease and on immunotherapy were largely excluded from seminal vaccine trials. This has led to significant vaccine hesitancy in patients with neuroinflammatory diseases (NID); including, but not limited to: multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), neurosarcoidosis and myelin oligodendrocyte antibody-mediated disease (MOG-AD). Data is urgently needed to help guide clinical care in the NID population. Methods: This was a cross-sectional observational study evaluating adults with a neurologist-confirmed diagnosis of a neuroinflammatory disease (NID) and a neurologically asymptomatic control population. Participants were recruited from multiple academic centers in the MS Resilience to COVID-19 Collaborative study. We analyzed participant responses from a vaccine-specific questionnaire collected between February and May 2021. Results: 1164 participants with NID and 595 controls completed the vaccine survey. Hesitancy rates were similar between NID and control groups (n=134, 32.7% NID vs. n=56, 30.6% control; p=0.82). The most common reasons for hesitancy in NID participants were lack of testing in the autoimmune population and fear of demyelinating/neurologic event. Unvaccinated patients who had discussed vaccination with their doctor were less likely to be hesitant (n=184, 73.6% vs. n=83, 59.7%; p=0.007). 634 NID patients and 332 controls had received at least one dose of a vaccine against SARS-CoV-2 at the time of survey completion. After adjusting for age, BMI, and comorbidities, there was no difference in self-reported side effects (SE) between groups with the first dose (n=256, 42.2% NID vs. 141, 45.3% control; p=0.20) or second dose (n=246, 67.0% NID vs. n=114, 64.8% control, p=0.85) of the mRNA vaccines nor with the viral-vector vaccines (n=6, 46% NID vs. n= 8, 66% control; p= 0.39). All reported SEs fell into the expected SE profile. There was no difference in report of new/recurrent neurologic symptoms (n = 110, 16.2% vaccinated vs. 71, 18.2% unvaccinated; p =0.44) nor radiologic disease activity (n=40, 5.9% vaccinated vs. n=30, 7.6% unvaccinated) between vaccinated and unvaccinated NID participants. Conclusions: We found no difference in patient-reported vaccine side effects and no evidence of NID worsening after vaccination. Large-scale real-world evidence is needed for further validation. Achieving herd immunity against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a vital component to overcoming the Coronavirus Disease of 2019 (COVID- 19) pandemic. Vaccine hesitancy is a major barrier to accomplishing this goal and is considered a top threat to global health by the World Health Organization (WHO). 1 Hesitancy is especially apparent in patients with autoimmune diseases, such as multiple sclerosis (MS), who were largely excluded from vaccine seminal trials and are often on immunotherapy that may reduce vaccine response. 2 Preliminary data suggest that hesitancy in the autoimmune population is primarily due to fear of side effects and worsening of their underlying disease. 3, 4 While data relating to COVID-19 vaccines remain limited in the neuroinflammatory disease population, one study to date in MS reported no safety concerns nor increased risk of MS relapse after the Pfizer/BioNTech BNT162b2 vaccine. 5 For many other well-established vaccines, it has been shown that the benefits of vaccination in patients with MS and related disorders strongly outweigh the risks of contracting the associated infection. 6, 7 Accordingly, the WHO and Centers for Disease Control (CDC) have encouraged vaccination against COVID-19 for patients with autoimmune disease, as has the National MS Society (NMSS) for those with MS. [8] [9] [10] In this study, we assessed vaccine hesitancy and evaluated early vaccine safety/tolerability in patients with MS and other neuroinflammatory diseases (NID) by leveraging an existing network of MS Centers that are part of the MS Resilience to COVID-19 (MSReCOV) Collaborative. This was a cross-sectional observational study evaluating participants recruited from multiple MS centers participating in the MSReCOV Collaborative, 11 1164 patients with NID and 595 neurologically asymptomatic control patients completed the initial vaccine survey. Sociodemographic information, neurologic history and functional status are provided in Table I . Notably, patients in the NID group were older, had a higher mean CCI, and lower mean BMI than control patients. These factors were controlled for in subsequent analyses. NID patients had a mean disease duration of 18.8 (SD ±13.3) years and mean PDDS of 2.21 (SD ± 2.5). Disability level was determined at the time of vaccine survey completion for all participants using the patient determined disease steps (PDDS) scoring scale, ranging from 0 (no disability) to 8 (bedridden) as outlined further in the methods section of the main text. f Disease modifying therapy at the time of vaccination is shown. B-cell therapies included: ocrelizumab (n=168, 24%), rituximab (n = 38, 5.5%), ofatumumab (n=2, 0.3%). Interferons included: interferon beta-1a IM (n=47, 6.28) and SC (n=17, 2.5%), and pegylated interferon beta-1a (n=12, 1.7%), interferon beta-1b (n=6, 0.9%). Fumarates included dimethyl fumarate (n=45, 6.5%) and diroximel fumarate (n=5, 0.7%). S1P receptor modulators included: fingolimod (n=40, 5.1%), siponomid (n=3, 0.4%), and ozanimod (n=1, 0.2%). Abbreviations: MS= multiple sclerosis, NID= neuroinflammatory disease; SD= standard deviation; BMI= Body Mass Index; CCI= Charlson Comorbidity Index; PDDS: patient determined disease steps; DMT = disease modifying therapy. S1P= sphingosine-1-phosphate. Figure 1 ; A]. The most common reasons for hesitancy in NID patients were lack of testing in the autoimmune population (n=37, 58.7%), fear of a new demyelinating event and/or neurologic symptom (n=33, 52.4%), and worry that the vaccines are too new (n=26, 41.3%) [ Figure 1 ; B]. Approximately half of NID patients (n=32, 50.8%) who did not plan to be vaccinated did not previously receive the influenza and/or other recommended vaccines, most commonly due to personal preference (n=14, 45.2%) or fear of an autoimmune reaction (n=11, 35.5%). NID participants who had discussed vaccination with their neurological healthcare professional were less hesitant than the participants who had not discussed vaccination with their neurologists p=0.007. Among those who had the discussion, the hesitancy rate was lower when the neurologists recommended vaccination during their discussion (p < 0.0001). P-values in the figure refer to comparison of hesitancy rates between indicated groups. *23 patients were not sure if they had discussed the vaccine with their neurologists and were excluded from this figure. (B) Vaccine Hesitancy Reasons. Patients who responded "No" to the question, "Do you plan to be vaccinated against COVID-19?" were asked to select the reason(s) why they did not want to be vaccinated. Participants were able to select more than one reason. Responses from both the MS/NID group (navy, n= 134) and control group (n=56) are displayed here. MS/NID patients were more likely to report fear of a neurologic and/or demyelinating event as reasons they would not get vaccinated. *Answers provided as free text for "Other" in both groups most commonly included: perceiving oneself as low risk for contracting COVID-19, vaccines only having emergency use authorization, and fear of unknown long term side effects. Abbreviations: MS (multiple sclerosis), NID (neuroinflammatory disease). There was no difference in rate of reported side effects for those on standard-efficacy therapy (n=31, 37.6%, RR 0.81, p=0.34) compared to those not on medication for the second dose. However, when adjusting for age, BMI, and comorbidities, treatment with standard-efficacy therapy was associated with a lower risk of reported side effects (p=0.03) than NID patients not on medication for the mRNA vaccines, and there was no longer an association between high-efficacy therapy and reported side effects with any dose. Comparison of patient-reported side effects following all doses of vaccination against SARS-CoV-2 are reported here. p-values represent comparison between the NID and control group. There were no significant differences in reported side effect rates between the groups. However, when adjusting for age, comorbidities, and vaccine type, there was a higher rate of side effects reported after the second dose of the mRNA vaccines. The only difference in side effect type between groups was an increase in headaches reported by the NID group after the mRNA vaccines. Other" free text responses for all vaccine doses fell into the categories of: lymphadenopathy, joint pain, myalgias, chest pain, light-headedness/dizziness and rash. There were no differences between sub-categories of "other" responses between NID and control. d Neurologic complications listed by the MS/NID group in free text form who indicated a neurologic complication as side effect of a 2-dose vaccine series included "worsening of numbness and coordination", "worsening of MS symptoms -weakness of muscles and loss of balance", and "mental pain related to MS." The remaining participants (n=1 first dose, and n=4 second dose) did not specify. All NID participants evaluated here were enrolled in the previously established MSReCOV study, which The lack of available data evaluating the effect of vaccines against SARS-CoV-2 in patients with neuroinflammatory disease is a major cause of vaccine hesitancy and a potential obstacle to optimizing patient safety and public health. In our study, we found similar rates of hesitancy between a large group of patients with NID and a neurologically asymptomatic control group. Our results confirmed that the most common reasons for vaccine hesitancy in the NID group were related to lack of data in the autoimmune population and fear of worsening of underlying neurologic disease. Importantly, we found a lower vaccine hesitancy rate among participants who had discussed vaccination with their neurologic healthcare provider than those who did not have such discussion. The difference in vaccine hesitancy rate was also more pronounced when the clinicians had recommended vaccination. Taken together, our findings suggest that clinicians can decrease vaccine hesitancy in the NID population through patient education and counseling. Our results highlight the need for further SARS-CoV-2 vaccine studies in the NID population to improve patient reassurance. In our early analysis, we found no overall difference in reported side effect rates between the NID and control group for all vaccine types and doses. This remained true after adjusting for population differences, including age, BMI, and comorbidities. When examining the side effect profiles, headache was the only side effect reported at higher rates in NID patients than the controls. This finding could be due to worsening of underlying headache disorders, which are more prevalent in patients with multiple sclerosis (i.e. majority of the NID group). 18 Notably, there was no new side effect signal for either the NID or control group when compared to published SARS-CoV-2 vaccine trials. [19] [20] [21] [22] With the second dose of the mRNA vaccines, we found that being on high-efficacy therapy (prior to adjustment for population differences) or standard-efficacy therapy at the time of vaccination correlated with a lower rate of side effects. While difficult to know based on our current study, we speculate that this finding could be related to an attenuated immune response. Thus far, decreased humoral response to the COVID-19 mRNA vaccine has been most convincingly shown for certain high-efficacy therapies, such as B-cell depleting therapies, S1P-receptor modulating therapies, and within the first four months of cladribine dosing. 16 Further studies will be needed to determine the impact of immunotherapy on the rate and severity of side effects experienced. There was no difference in the rate of recurrent/new neurologic symptoms or radiologic disease activity between vaccinated and unvaccinated patients with NID during the inter-survey time interval within the MSReCOV study. Among those who experienced new symptoms, the types of symptoms reported were also the same between vaccinated and unvaccinated participants. However, we note that for this initial evaluation, a large proportion of the inter-survey time interval occurred prior to vaccination and therefore may not accurately represent the effect of vaccination on underlying disease activity. Continued monitoring is necessary prior to drawing any conclusions. When honing in on the small subset of patients (1.5%) with onset of a neurologic symptom after vaccination, we cannot conclude whether these symptoms were vaccine-related. It is reassuring that the majority of these events occurred at least one month after vaccination (60%) and had no known MRI correlation. Further, 9 out of 10 individuals did not require any acute symptomatic treatment. In our study, no patients with NID were diagnosed with COVID-19 after completing their vaccination. It is worth noting that many patients were on DMTs that could reduce vaccine efficacy. 2, 16, 17, 23, 24 We note the relatively short follow-up duration and therefore strongly caution against false reassurance from our results, as our goal of this initial report is for timely dissemination of early findings to guide clinical care. Several strengths of this study are worth noting. For one, we leveraged a previously established network of MS centers (e.g. the MSReCOV Collaborative) for wide and rapid survey deployment. This enabled us to generate prompt real-world data focused on the understudied topic of COVID-19 vaccination in patients with NID. Second, our cohort was large and had detailed information available regarding demographics, clinical history, disability level and several vaccine-related topics. Finally, we utilized a sizable population of neurologically asymptomatic participants as a control group, allowing us to assess if any vaccinerelated side effects were unique to the NID population. Our study also had several limitations. First, patients with NID differed from controls in age and comorbidities, both of which may affect side effect rates. We controlled for these differences when evaluating side effect profiles to reduce confounding. Second, our findings may have limited generalizability, as study participants predominantly identified as being of non-Hispanic European descent and a subset of the control participants were neurologically asymptomatic first-degree relatives of individuals with autoimmune disease. Third, the findings described here relied on self-report, though survey response is a reasonable method that enables rapid data collection for a timely investigation. Fourth, there may be recall bias as a large proportion of patients had been vaccinated prior to survey distribution, again highlighting the choice for survey deployment in existing research participants. Lastly, in attempt for prompt data acquisition, the overall follow up time after vaccination is limited. As the pandemic persists and the need for booster rises, we are continuing with longitudinal follow-up to evaluate the safety/tolerability and efficacy of SARS-CoV-2 vaccines in this patient population. Overall, our findings suggest that SARS-CoV-2 vaccines in patients with neuroinflammatory disease are safe and unlikely to worsen underlying disease activity. This is consistent with evidence from other vaccines in MS. 2, 5 In contrast, we note that COVID-19 is associated with a variety of inflammatory and non-inflammatory neurologic complications, which should be considered in the risk/benefit discussion regarding vaccination. [25] [26] [27] Our study highlights the utility of patient education by clinicians and the need for inclusion of this population in future vaccine trials to ensure that the vast majority of this vulnerable population is well protected from novel infections. Zongqi Xia serves on the advisory board for Roche/Genentech; he has sponsored research agreements with Octave Biosciences Genzyme, Alexion, Biogen. She has received research funding from Genentech Christopher Perrone has served on an advisory board/consulted for: EMD Serono and Novartis Bianca Weinstock-Guttman has participated in speaker's bureaus and/or served as a consultant for Weinstock-Guttman also has received grant/research support from the agencies listed in the previous sentence Riley has served on an advisory board/consulted for: Genentech/Roche; Biogen; Novartis Bristol Myers Squibb; Janssen Global De Jager serves on advisory board for: Biogen; Merck Serono; and Roche; he has sponsored research agreements with Roche Rebecca Farber has served on advisory board / consulted for: Roche/ Genentech Wesley has sponsored agreements with the NIH and Novartis. REFERENCES 1. World Health Organization. Ten threats to global health in 2019 COVID-19 and Vaccination in the Setting of Neurologic Disease: An Emerging Issue in Neurology Perspective of patients with autoimmune diseases on COVID-19 vaccination Determinants of Vaccination Uptake in Risk Populations: A Comprehensive Literature Review. Vaccines (Basel) 2020 COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by Practice guideline update summary: Vaccinepreventable infections and immunization in multiple sclerosis A large case-control study on vaccination as risk factor for multiple sclerosis COVID-19 Vaccines for People with Underlying Medical Conditions World Health Organization. COVID-19 advice for the public: Getting vaccinated Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk A new method of classifying prognostic comorbidity in longitudinal studies: development and validation Disease steps in multiple sclerosis: a simple approach to evaluate disease progression Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies COVID-19 vaccination and antirheumatic therapy The prevalence of migraine in multiple sclerosis (MS): A systematic review and meta-analysis Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Safety and immunogenicity of the vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and Efficacy of the BNT162b2 mRNA Covid-19 Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Safety and efficacy of COVID-19 vaccines in multiple sclerosis patients High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases Neurological associations of COVID-19 Immune-mediated neurological syndromes in SARS-CoV-2-infected patients SARS-CoV-2 and nervous system: From pathogenesis to clinical manifestation The authors received no financial support for the research, authorship, and/or publication of this article.